Eisai Launches "TAMBOCOR Injection 50mg" an Antiarrthymic Treatment.
Tokyo (November 30, 1998) - Eisai Co., Ltd. of Tokyo (President and CEO:Haruo Naito) today announced the launch on November 27 of an antiarrthymic injection agent, TAMBOCOR Injection 50 mg (generic name:flecainide acetate).
TAMBOCOR Injection 50 mg is in the Ic class of the Vaughan-Williams classification of antiarrhymic agents. The product can be given in emergency cases or when other antiarrthymic agents are not expected to demonstrate efficacy.
In Japan the number of patients suffering from arrthymias needing acute care is estimated to be 1.1 million yearly and these patients require a treatment delivering immediate and strong efficacy. The high efficacy of TAMBOCOR Injection 50 mg is reflected in the NHI drug price supplemental classification II.
TAMBOCOR was discovered in 1972 by 3M Pharmaceuticals of the U.S. and has been widely used in foreign countries. In Japan joint clinical trials were begun in 1984 with 3M Pharmaceuticals and the oral formulation of TAMBOCOR was launched in 1991.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of about $2.3 billion in 1997 with approximately 16 percent of sales spent for research and development.
TAMBOCOR is a registered trademark of 3M Pharmaceuticals.